Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 9/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406340 | 1.00 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1406870 | 0.90 | RARB (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1406867 | 0.90 | RARB (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1406432 | 0.90 | MAOB (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1406431 | 0.90 | MAOB (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1406430 | 0.89 | RARB (0.35) | HDAC6APPRARARARBRARG | |
| SCHEMBL1406424 | 0.88 | RARB (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1406423 | 0.88 | RARB (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6422662 | 0.87 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6424149 | 0.83 | RARA (0.40) | RARARARBRARGDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513793-B1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2011-03-09 | — | — | EP | claimed |
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | US | claimed |
| EP-1513793-B1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2011-03-09 | — | — | EP | disclosed |
| US-7468457-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1513793-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101928-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | HDAC3 1804/4885HDAC4 2116/4885HDAC1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.